Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?

被引：19

作者：

Dirican, Ahmet ^{[1
]}

Varol, Umut ^{[1
]}

Kucukzeybek, Yuksel ^{[1
]}

Alacacioglu, Ahmet ^{[1
]}

Erten, Cigdem ^{[1
]}

Somali, Isil ^{[3
]}

Can, Alper ^{[1
]}

Demir, Lutfiye ^{[1
]}

Bayoglu, Ibrahim Vedat ^{[1
]}

Akyol, Murat ^{[1
]}

Yildiz, Yasar ^{[1
]}

Koyuncu, Betul ^{[2
]}

Coban, Eyup ^{[2
]}

Tarhan, Mustafa Oktay ^{[3
]}

机构：

[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey

[2] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Internal Med, Izmir, Turkey

[3] Dokuz Eylul Univ, Dept Med Oncol, Inst Oncol, Izmir, Turkey

来源：

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2014年 / 15卷 / 12期

关键词：

Metastatic colorectal cancer; bevacizumab; neutrophil to lymphocyte ratio; response to therapy; COOPERATIVE-ONCOLOGY-GROUP; 1ST-LINE TREATMENT; LYMPHOCYTE RATIO; CONTROLLED-TRIAL; ORAL FLUOROPYRIMIDINES; NEUTROPHIL; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; EFFICACY;

D O I：

10.7314/APJCP.2014.15.12.4781

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The purpose of this study was to analyze the predictive value of neutrophil/lymphocyte ratio (NLR) to better clarify which patient groups will benefit the most from particular treatments like bevacizumab. Materials and Methods: A total of 245 treatment-naive metastatic colorectal cancern (mCRC) patients were retrospectively enrolled and divided into 2 groups: 145 group A patients were treated with chemotherapy in combination with bevacizumab, and 100 group B patients were treated as above without bevacizumab. Results: Group A patients had better median overall survival (OS) and progression-free survival (PFS) (24.0 and 9.0 months) than group B patients (20 and 6.0 months) (p=0.033; p=0.015). In patients with low NLR, OS and PFS were significantly longer in group A patients (27 vs 18 months, p=0.001; 11 vs 7 months, p=0.017). Conclusions: We conclude that NLR, a basal cancer related inflammation marker, is associated with the resistance to bevacizumab-based treatments in mCRC patients.

引用

页码：4781 / 4786

页数：6

共 35 条

[1] Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients [J].

Abajo, A. ;

Boni, V. ;

Lopez, I. ;

Gonzalez-Huarriz, M. ;

Bitarte, N. ;

Rodriguez, J. ;

Zarate, R. ;

Bandres, E. ;

Garcia-Foncillas, J. .

BRITISH JOURNAL OF CANCER, 2012, 107 (02) :287-290

[2] VASCULAR REACTIONS OF NORMAL AND MALIGNANT TISSUES INVIVO .1. VASCULAR REACTIONS OF MICE TO WOUNDS AND TO NORMAL AND NEOPLASTIC TRANSPLANTS [J].

ALGIRE, GH ;

CHALKLEY, HW .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1945, 6 (01) :73-85

[3] Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients [J].

Botta, Cirino ;

Barbieri, Vito ;

Ciliberto, Domenico ;

Rossi, Antonio ;

Rocco, Danilo ;

Addeo, Raffaele ;

Staropoli, Nicoletta ;

Pastina, Pierpaolo ;

Marvaso, Giulia ;

Martellucci, Ignazio ;

Guglielmo, Annamaria ;

Pirtoli, Luigi ;

Sperlongano, Pasquale ;

Gridelli, Cesare ;

Caraglia, Michele ;

Tassone, Pierfrancesco ;

Tagliaferri, Pierosandro ;

Correale, Pierpaolo .

CANCER BIOLOGY & THERAPY, 2013, 14 (06) :469-475

[4] Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer [J].

Cedres, S. ;

Torrejon, D. ;

Martinez, A. ;

Martinez, P. ;

Navarro, A. ;

Zamora, E. ;

Mulet-Margalef, N. ;

Felip, E. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (11) :864-869

[5] Relationship Between Prognosis and Neutrophil: Lymphocyte and Platelet: Lymphocyte Ratios in Patients with Malignant Pleural Mesotheliomas [J].

Cihan, Yasemin Benderli ;

Ozturk, Ahmet ;

Mutlu, Hasan .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) :2061-2067

[6] An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT] [J].

Clarke, Stephen ;

Burge, Matt ;

Cordwell, Cassandra ;

Gibbs, Peter ;

Reece, William ;

Tebbutt, Niall .

BMC CANCER, 2013, 13

[7] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[8]

Ducreux J, 2007, J CLIN ONCOL, V25, P170

[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[10] Angiogenesis as a therapeutic target [J].

Ferrara, N ;

Kerbel, RS .

NATURE, 2005, 438 (7070) :967-974

← 1 2 3 4 →